Scientists have developed a novel approach of genome editing to repair muscle stem (satellite) cells, offering new hope for ...

In 2025, CRISPR advanced gene editing with safe, effective therapies and AI tools, marking a shift towards real-world ...

The top 10 PharmTech videos of the year cover advanced therapies, high-concentration biologics, major mergers and ...

As of Tuesday, December 30, Ultragenyx Pharmaceutical Inc.’s RARE share price has surged by 9.99%, which has investors questioning if this is right time to sell.

D Molecular Therapeutics, Inc. (NASDAQ:FDMT) is among the Best Get Rich Fast Stocks to Buy Right Now. As of December 24, 4D ...

As December draws to a close and Christmas arrives, investors are pausing to look back and assess a year that never followed a simple script. Policy uncertainty lingered, and trade headlines remained ...

The firm submitted non-clinical and clinical modules of its rolling BLA for DTX401 in August and has now submitted the chemistry, manufacturing, and controls module.

Patients submitted for consideration for treatment with GS010/Lumevoq must meet specific eligibility criteria, including the length of time since the onset of their vision loss.

According to DataM Intelligence, the global cell and gene therapy market reached a value of US$13.90 billion in 2024 and is ...